By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries and these numbers suggest a potential market for ExoPTEN of approximately 50,000 new cases globally per year—an enormous market potential with patients eager to … Read more
By Michael Kim NASDAQ:QSG READ THE FULL QSG RESEARCH REPORT Pre-market open on 11/27/24, QuantaSing (NASDAQ:QSG) reported F1Q25 (Sep) earnings results. On a GAAP basis, QSG reported net income of $11.5 million for F1Q25, or $0.21 per ADS. That said, excluding share-based compensation expenses, adjusted EPS came in at $0.23, or below our estimate of … Read more
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with the U.S. Food and Drug Administration (FDA) following an ‘End-of-Phase 2’ meeting on the company’s proposed plan for a Phase … Read more
By David Bautz, PhD NASDAQ:FBLG READ THE FULL FBLG RESEARCH REPORT Business Update On Track to Initiate Phase 1/2 Trial in Diabetic Foot Ulcers FibroBiologics, Inc. (NASDAQ:FBLG) is on track to initiate a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product candidate, in patients suffering from diabetic foot ulcers (DFU) in the second quarter … Read more
By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT Monogram (NASDAQ:MGRM) reported 3rd quarter 2024 financial results on November 14th which were largely in line with expectations. Research and development expenses for the quarter ending September 30, 2024 were $2.2 million compared to $2.7 million in the prior year period. The R&D decrease … Read more
